AT350735B
(de)
*
|
1976-08-06 |
1979-06-11 |
Hoffmann La Roche |
Verfahren zur herstellung von neuen ribo- furanosyl-imidazolderivaten
|
US4863743A
(en)
*
|
1985-02-19 |
1989-09-05 |
Key Pharmaceuticals, Inc. |
Controlled release potassium chloride
|
IE59066B1
(en)
*
|
1985-02-19 |
1993-12-15 |
Key Pharma |
Controlled release potassium chloride
|
GB8519310D0
(en)
*
|
1985-07-31 |
1985-09-04 |
Zyma Sa |
Granular active substances
|
US4971791A
(en)
*
|
1985-08-26 |
1990-11-20 |
The Procter & Gamble Company |
Taste masking compositions
|
GB8521494D0
(en)
*
|
1985-08-29 |
1985-10-02 |
Zyma Sa |
Controlled release tablet
|
US5624683A
(en)
*
|
1986-08-06 |
1997-04-29 |
Eisai Co., Ltd. |
Sustained-release multi-granule tablet
|
IT1197316B
(it)
*
|
1986-10-01 |
1988-11-30 |
Proter Spa |
Formulazione galenica ad uso orale di derivati della reina a lento rilascio per impiego terapeutico
|
US4800087A
(en)
*
|
1986-11-24 |
1989-01-24 |
Mehta Atul M |
Taste-masked pharmaceutical compositions
|
GB8628359D0
(en)
*
|
1986-11-27 |
1986-12-31 |
Zyma Sa |
Galenical formulation
|
DE3776116D1
(de)
*
|
1986-12-30 |
1992-02-27 |
American Cyanamid Co |
Zusammensetzung die ein polycarbophil enthaelt.
|
GB8707416D0
(en)
*
|
1987-03-27 |
1987-04-29 |
Wellcome Found |
Pharmaceutical formulations
|
GB8707421D0
(en)
*
|
1987-03-27 |
1987-04-29 |
Wellcome Found |
Pharmaceutical formulations
|
US4789547A
(en)
*
|
1987-06-17 |
1988-12-06 |
Warner-Lambert Company |
Transdermal matrix system
|
US4904477A
(en)
*
|
1987-07-08 |
1990-02-27 |
American Home Products Corporation |
Spray dried ibuprofen compositions
|
US4927639A
(en)
*
|
1989-02-02 |
1990-05-22 |
Warner-Lambert Company |
Modified release gemfibrozil composition
|
US5122384A
(en)
*
|
1989-05-05 |
1992-06-16 |
Kv Pharmaceutical Company |
Oral once-per-day organic nitrate formulation which does not induce tolerance
|
US5133974A
(en)
*
|
1989-05-05 |
1992-07-28 |
Kv Pharmaceutical Company |
Extended release pharmaceutical formulations
|
DE3937455A1
(de)
*
|
1989-11-10 |
1991-05-16 |
Nordmark Arzneimittel Gmbh |
Antacidatabletten
|
EP0462066A1
(en)
*
|
1990-06-15 |
1991-12-18 |
Warner-Lambert Company |
Amorphous gemfibrozil
|
US5629016A
(en)
*
|
1991-01-30 |
1997-05-13 |
Glaxo Wellcome Inc. |
Water-dispersible tablets
|
GB2257363B
(en)
*
|
1991-01-30 |
1994-09-28 |
Wellcome Found |
Water dispersible tablets containing acyclovir
|
ES2059260B1
(es)
*
|
1992-10-06 |
1995-04-16 |
Espanola Prod Quimicos |
Procedimiento de preparacion de comprimidos conteniendo diclofenaco; dispersables en agua.
|
DE4317172A1
(de)
*
|
1993-05-22 |
1995-01-05 |
Rhone Poulenc Rorer Gmbh |
Geschmacksneutrale und schnellfreisetzende Buflomedil-Hydrochlorid-Arzneiform und Herstellungsverfahren desselben
|
US5698226A
(en)
*
|
1993-07-13 |
1997-12-16 |
Glaxo Wellcome Inc. |
Water-dispersible tablets
|
ES2082723B1
(es)
*
|
1994-07-20 |
1996-10-01 |
Lilly Sa |
Formulacion farmaceutica de fluoxetina en forma dispersable.
|
US5674529A
(en)
*
|
1995-06-06 |
1997-10-07 |
Church & Dwight Co., Inc. |
Alkalinizing potassium salt controlled release preparations
|
DE69633018T2
(de)
*
|
1995-11-14 |
2004-12-09 |
Abbott Gmbh & Co. Kg |
Schilddrüsenhormone enthaltende stabilisierte arzneimittel und verfahren
|
US5773031A
(en)
*
|
1996-02-27 |
1998-06-30 |
L. Perrigo Company |
Acetaminophen sustained-release formulation
|
EP0906754B1
(en)
*
|
1996-04-26 |
2002-12-11 |
Shionogi & Co., Ltd. |
Rapid-release s1452 tablets
|
FR2766089B1
(fr)
*
|
1997-07-21 |
2000-06-02 |
Prographarm Lab |
Comprime multiparticulaire perfectionne a delitement rapide
|
HU221435B
(en)
*
|
1998-02-20 |
2002-10-28 |
Egyt Gyogyszervegyeszeti Gyar |
Pellet-based pharmaceutical composition of controlled release with high content of potassium-chloride, and process for it's production
|
FR2781793B1
(fr)
*
|
1998-08-03 |
2001-07-20 |
Prographarm Lab |
Procede de fabrication de granules de gabapentine enrobes
|
US6432448B1
(en)
|
1999-02-08 |
2002-08-13 |
Fmc Corporation |
Edible coating composition
|
US6723342B1
(en)
|
1999-02-08 |
2004-04-20 |
Fmc Corporation |
Edible coating composition
|
US6500462B1
(en)
|
1999-10-29 |
2002-12-31 |
Fmc Corporation |
Edible MCC/PGA coating composition
|
US6399101B1
(en)
|
2000-03-30 |
2002-06-04 |
Mova Pharmaceutical Corp. |
Stable thyroid hormone preparations and method of making same
|
DE60128215T2
(de)
|
2000-04-20 |
2008-01-10 |
Novartis Ag |
Beschichtungszusammensetzung zur geschmacksmaskierung
|
US6932861B2
(en)
*
|
2000-11-28 |
2005-08-23 |
Fmc Corporation |
Edible PGA coating composition
|
BR0115585A
(pt)
|
2000-11-28 |
2005-12-13 |
Fmc Corp |
Composições de revestimento de pronta liberação, endurecìvel, comestìvel, seca e, úmida, forma de dosagem sólida, e, método para revestir uma forma de dosagem sólida farmacêutica ou veterinária, confeito, semente, ração animal, fertilizante, comprimido de pesticida ou alimento
|
US20030224047A1
(en)
*
|
2001-02-15 |
2003-12-04 |
Franz G. Andrew |
Levothyroxine compositions and methods
|
JP2004525109A
(ja)
*
|
2001-02-15 |
2004-08-19 |
キング・ファーマシューティカルズ・インコーポレイティッド |
安定化された甲状腺ホルモン医薬組成物、及びその製法
|
US6555581B1
(en)
|
2001-02-15 |
2003-04-29 |
Jones Pharma, Inc. |
Levothyroxine compositions and methods
|
US20030032675A1
(en)
*
|
2001-02-15 |
2003-02-13 |
Franz G. Andrew |
Manufacture of thyroid hormone tablets having consistent active moiety amounts
|
US20030180353A1
(en)
*
|
2001-08-10 |
2003-09-25 |
Franz G. Andrew |
Stabilized pharmaceutical compositions
|
US20030198667A1
(en)
*
|
2001-08-10 |
2003-10-23 |
Franz Andrew G. |
Methods of producing dispersible pharmaceutical compositions
|
US20030198671A1
(en)
*
|
2001-08-10 |
2003-10-23 |
Franz G. Andrew |
Levothyroxine compositions having unique plasma AUC properties
|
US20030190349A1
(en)
*
|
2001-08-10 |
2003-10-09 |
Franz G. Andrew |
Methods of stabilizing pharmaceutical compositions
|
US20030195253A1
(en)
*
|
2001-08-14 |
2003-10-16 |
Franz G. Andrew |
Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
|
US20030198672A1
(en)
*
|
2001-08-14 |
2003-10-23 |
Franz G. Andrew |
Levothyroxine compositions having unique triidothyronine plasma AUC properties
|
US20030199586A1
(en)
*
|
2001-08-14 |
2003-10-23 |
Franz G. Andrew |
Unique levothyroxine aqueous materials
|
US20030199587A1
(en)
*
|
2001-08-14 |
2003-10-23 |
Franz G. Andrew |
Levothyroxine compositions having unique Cmax properties
|
US7101569B2
(en)
|
2001-08-14 |
2006-09-05 |
Franz G Andrew |
Methods of administering levothyroxine pharmaceutical compositions
|
US20030203967A1
(en)
*
|
2001-08-14 |
2003-10-30 |
Franz G. Andrew |
Levothyroxine compositions having unique Tmax properties
|
US20040043066A1
(en)
*
|
2001-10-29 |
2004-03-04 |
Franz G. Andrew |
Levothyroxine compositions having unique triiodothyronine Tmax properties
|
US6645526B2
(en)
*
|
2001-11-13 |
2003-11-11 |
Mylan Pharmaceuticals, Inc. |
Storage stable thyroxine active drug formulations and methods for their production
|
US20030099699A1
(en)
|
2001-11-13 |
2003-05-29 |
Hanshew Dwight D. |
Storage stable thyroxine active drug formulations and methods for their production
|
AU2003221326A1
(en)
*
|
2002-03-06 |
2003-09-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Tablets quickly disintegrating in oral cavity
|
US20040029959A1
(en)
*
|
2002-08-08 |
2004-02-12 |
John Devane |
Isosorbide mononitrate compositions and methods of their use
|
US7632521B2
(en)
*
|
2003-07-15 |
2009-12-15 |
Eurand, Inc. |
Controlled release potassium chloride tablets
|
AU2007266574A1
(en)
*
|
2006-06-01 |
2007-12-06 |
Dexcel Pharma Technologies Ltd. |
Multiple unit pharmaceutical formulation
|
EP2101738A2
(en)
*
|
2006-12-21 |
2009-09-23 |
Mallinckrodt Inc. |
Composition of and method for preparing orally disintegrating tablets
|
CA2673458A1
(en)
*
|
2006-12-21 |
2008-07-03 |
Mallinckrodt Inc. |
Composition of and method for preparing orally disintegrating tablets containing a high dose of pharmaceutically active ingredients
|
CN101380474B
(zh)
*
|
2007-09-06 |
2012-07-25 |
北京大学 |
用于口服制剂的pH敏感性固体药物组合物及制备方法
|
CA2936748C
(en)
|
2014-10-31 |
2017-08-08 |
Purdue Pharma |
Methods and compositions particularly for treatment of attention deficit disorder
|
EP3288556A4
(en)
|
2015-04-29 |
2018-09-19 |
Dexcel Pharma Technologies Ltd. |
Orally disintegrating compositions
|
US10076494B2
(en)
|
2016-06-16 |
2018-09-18 |
Dexcel Pharma Technologies Ltd. |
Stable orally disintegrating pharmaceutical compositions
|
US10722473B2
(en)
|
2018-11-19 |
2020-07-28 |
Purdue Pharma L.P. |
Methods and compositions particularly for treatment of attention deficit disorder
|